Related Experiment Video
Updated: Apr 27, 2026

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling
Published on: October 28, 2014
Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis
Carlos DeOcesano-Pereira1, Murilo S Amaral1, Kleber S Parreira1
1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-900 São Paulo, SP, Brasil.
Abstract:
BCL-X mRNA alternative splicing generates pro-apoptotic BCL-XS or anti-apoptotic BCL-XL gene products and the mechanism that regulates splice shifting is incompletely understood. We identified and characterized a long non-coding RNA (lncRNA) named INXS, transcribed from the opposite genomic strand of BCL-X, that was 5- to 9-fold less abundant in tumor cell lines from kidney, liver, breast and prostate and in kidney tumor tissues compared with non-tumors. INXS is an unspliced 1903 nt-long RNA, is transcribed by RNA polymerase II, 5'-capped, nuclear enriched and binds Sam68 splicing-modulator. Three apoptosis-inducing agents increased INXS lncRNA endogenous expression in the 786-O kidney tumor cell line, increased BCL-XS/BCL-XL mRNA ratio and activated caspases 3, 7 and 9. These effects were abrogated in the presence of INXS knockdown. Similarly, ectopic INXS overexpression caused a shift in splicing toward BCL-XS and activation of caspases, thus leading to apoptosis. BCL-XS protein accumulation was detected upon INXS overexpression. In a mouse xenograft model, intra-tumor injections of an INXS-expressing plasmid caused a marked reduction in tumor weight, and an increase in BCL-XS isoform, as determined in the excised tumors. We revealed an endogenous lncRNA that induces apoptosis, suggesting that INXS is a possible target to be explored in cancer therapies.
Insights
A newly discovered long non-coding RNA, INXS, promotes apoptosis by shifting BCL-X splicing toward the pro-apoptotic BCL-XS isoform. This finding suggests INXS as a potential therapeutic target for cancer treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- RNA Biology
Background:
- Alternative splicing of BCL-X mRNA produces BCL-XS (pro-apoptotic) and BCL-XL (anti-apoptotic) isoforms.
- The regulatory mechanisms controlling BCL-X alternative splicing remain incompletely understood.
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in gene regulation and disease.
Purpose of the Study:
- To identify and characterize novel regulatory factors involved in BCL-X alternative splicing.
- To investigate the role of a newly identified lncRNA, INXS, in apoptosis and cancer.
- To explore the therapeutic potential of INXS in cancer treatment.
Main Methods:
- Identification and characterization of the INXS lncRNA.
- Analysis of INXS expression levels in tumor cell lines and tissues.
- Experimental manipulation of INXS expression (knockdown and overexpression) in cancer cells.
- Assessment of BCL-X splicing, apoptosis markers (caspases), and protein levels.
- In vivo studies using a mouse xenograft model.
Main Results:
- INXS lncRNA expression was significantly reduced in various tumor types compared to non-tumor samples.
- Increased INXS expression correlated with a shift in BCL-X splicing towards BCL-XS, caspase activation, and apoptosis.
- INXS knockdown abrogated apoptosis-inducing agent-mediated effects.
- Overexpression of INXS in vitro and in vivo led to BCL-XS accumulation and tumor growth inhibition.
- INXS binds to the Sam68 splicing modulator.
Conclusions:
- INXS is an endogenous lncRNA that regulates BCL-X alternative splicing to promote apoptosis.
- Reduced INXS expression is associated with multiple cancer types.
- INXS represents a promising novel therapeutic target for cancer treatment.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
Inheritance of Chromatin Structures
The Extrinsic Apoptotic Pathway
lncRNA - Long Non-coding RNAs
X-Inactivation
RNA Splicing

